Jama Pitman - Oct 28, 2023 Form 4 Insider Report for Deciphera Pharmaceuticals, Inc. (DCPH)

Role: Title: SVP, Regulatory, Quality, & Portfolio Management
Signature: /s/ Jeffrey M. Held, Attorney-in-Fact
Stock symbol: DCPH
Transactions as of: Oct 28, 2023
Transactions value $: -$16,909
Form type: 4
Date filed: 10/31/2023, 04:10 PM
Previous filing: Jun 21, 2023
Next filing: Dec 14, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	DCPH	Common Stock	Award		+5.58K	+12.64%		49.7K	Oct 28, 2023	Direct	F1, F2
transaction	DCPH	Common Stock	Sale	-$16.9K	-1.41K	-2.83%	$12.02	48.3K	Oct 30, 2023	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On February 15, 2023, the Reporting Person was granted restricted stock units ("RSUs"), which vest upon the satisfaction of three performance criteria. On October 28, 2023, the Issuer's Compensation Committee confirmed that performance criteria two had been met, resulting in the vesting of 5,576 RSUs.
F2	Includes 302 shares previously acquired under the Issuer's 2017 Employee Stock Purchase Plan.
F3	This sale was to cover tax liabilities in the vesting of RSUs.

Remarks:

Title: SVP, Regulatory, Quality, & Portfolio Management